
News|Articles|August 1, 2004
Ezetimibe/simvastatin
This novel dyslipidemia therapy features a combination of 2 previously approved drugs: ezetimibe and simvastatin. Ezetimibe exerts its effect by selectively inhibiting intestinal cholesterol and related phytosterol absorption. This mechanism of action is complemented by that of simvastatin, which acts through inhibition of the HMG-CoA reductase enzyme. The ezetimibe/simvastatin combination was approved on July 23, 2004, for the treatment of hypercholesterolemia and mixed hyperlipidemia
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Modernizing Pharmacy Benefit Administration: Addressing Legacy System Friction for Health Plans
2
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
3
Vitiligo is associated with mental heath conditions, other autoimmune diseases
4
Make lab monitoring of patents taking isotretinoin less routine, more based on symptoms
5
































